Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.
Phagenesis has raised $42.0M in total funding. The most recent round was Series D. The last funding was announced in March 2024.
Phagenesis's investors include Northern Gritstone, EQT Life Sciences, Aphelion Capital, Inventages Venture Capital Investment Inc., British Patient Capital.
Phagenesis is headquartered in Manchester, United Kingdom.
Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.
Phagenesis is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Phagenesis — Funding & Investors." VCBacked, March 4, 2024, https://www.vcbacked.co/company/phagenesis. Accessed July 20, 2026.
VCBacked. (2024). Phagenesis — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/phagenesis
{{cite web |title=Phagenesis — Funding & Investors |url=https://www.vcbacked.co/company/phagenesis |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated